289 related articles for article (PubMed ID: 23126308)
1. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation: a potential therapeutic strategy in oesophageal cancer.
Keeler BD; Brookes MJ
Br J Pharmacol; 2013 Mar; 168(6):1313-5. PubMed ID: 23278384
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
4. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
5. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
6. Iron chelators induce autophagic cell death in multiple myeloma cells.
Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
8. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation in the treatment of cancer: a new role for deferasirox?
Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
[TBL] [Abstract][Full Text] [Related]
10. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
11. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
12. Effects of iron depletion on CALM-AF10 leukemias.
Heath JL; Weiss JM; Lavau CP; Wechsler DS
Exp Hematol; 2014 Dec; 42(12):1022-1030.e1. PubMed ID: 25193880
[TBL] [Abstract][Full Text] [Related]
13. Nanog is a promising chemoresistant stemness marker and therapeutic target by iron chelators for esophageal cancer.
Narusaka T; Ohara T; Noma K; Nishiwaki N; Katsura Y; Kato T; Sato H; Tomono Y; Kikuchi S; Tazawa H; Shirakawa Y; Matsukawa A; Fujiwara T
Int J Cancer; 2021 Jul; 149(2):347-357. PubMed ID: 33662150
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
15. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Zhao Y; Rempe DA
J Cereb Blood Flow Metab; 2011 Jun; 31(6):1412-23. PubMed ID: 21245873
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
18. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Karnon J; Tolley K; Vieira J; Chandiwana D
Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
[TBL] [Abstract][Full Text] [Related]
19. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E
Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
[TBL] [Abstract][Full Text] [Related]
20. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]